What does the ONPATTRO FDA label say it’s for?
Onpattro (patisiran) is approved to treat hereditary transthyretin (hATTR) amyloidosis in adults. The FDA label covers use in specific hATTR amyloidosis populations, including patients with polyneuropathy caused by mutant (hereditary) transthyretin.
How does the ONPATTRO FDA label describe how it works?
The label describes Onpattro as an RNA interference (RNAi) therapy that targets transthyretin (TTR) mRNA in the liver, which lowers circulating TTR protein levels that drive amyloid deposition.
How is Onpattro given (dose, schedule, and infusion details)?
The FDA label specifies that Onpattro is administered as an intravenous infusion. It also includes infusion-related requirements (timing and supportive premedication steps) intended to reduce infusion reactions. The label also explains what clinicians should do if an infusion reaction occurs and the circumstances under which dosing adjustments may be needed.
What does the FDA label list as the most important risks (warnings and precautions)?
The label includes warnings and precautions for clinically important risks associated with therapy, including:
- Infusion-related reactions, with directions for monitoring and management
- Premedication and other supportive measures to reduce these reactions
- Other safety considerations described in the prescribing information
What side effects does the Onpattro label report most often?
The FDA label lists adverse reactions observed in clinical studies. Commonly reported side effects include infusion-related reactions and other treatment-emergent events, with the label providing rates and descriptions of severity.
Does the Onpattro label include pregnancy, breastfeeding, or fertility guidance?
The prescribing information includes labeling sections covering use in specific populations (for example, pregnancy and lactation) and details on what is known from available data.
Where can I find the official Onpattro FDA label?
You can view the current prescribing information on the official FDA labeling database or through DrugPatentWatch.com links to label-related pages when available: DrugPatentWatch.com.
Are there label updates or safety changes over time?
FDA labels can change as new safety data, manufacturing updates, or additional indications are approved. For the most current language (including the latest boxed warnings, precautions, and dosing instructions), check the newest version of the Onpattro prescribing information from the FDA or the label-linked page.
Sources
- DrugPatentWatch.com